A Phase 2 interventional study of LY2189265 and Placebo in Diabetes Mellitus Type 2, sponsored by Eli Lilly and Company. Completed at 34 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-10.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 24th largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 2, and was the 1st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 262 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 105th largest by enrollment of the 232 interventional ones that give a count, is one of 8 that started in 2008, is one of 34 in phase 2, and was the 29th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks
Drug: LY2189265
LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks
Drug: LY2189265
LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks
Drug: LY2189265
Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks
Drug: Placebo
Also known as: Dulaglutide
Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Once weekly injections of LY2189265 (titrated and non-titrated doses) compared to placebo on blood glucose were evaluated. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline glycosylated hemoglobin (HbA1c).
Time frame: Baseline, 16 weeks
Change From Baseline in Fasting Blood Glucose
Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means of change were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.
Time frame: Baseline, 16 weeks
Meal Test Glucose Excursion (Change in Blood Glucose to Test Meal)
Glucose excursion in response to a standardized solid mixed meal test was evaluated at baseline (randomization) and at Week 16, or at early termination. Each of the 2 standardized meal tests required participants to fast starting at 2200 hours the night prior to the test. A standardized breakfast meal was provided to the participant (approximately 550 kilocalorie \[Kcal\], 103 grams \[g\] carbohydrates, 22 g protein, and 8.5 g fat) and was to be consumed within 15 minutes. Serial venous blood samples were taken at the start of the meal (fasting \[0\]) and 30, 60, 90, 120, and 180 minutes after the start of the meal. Least Squares (LS) means of change in mean glucose area under the curve excursion following a test meal were calculated adjusting for treatment, combination of oral medications, and baseline.
Time frame: Baseline and 16 weeks
Change From Baseline in Daily Mean Blood Glucose Values From the 8-point Self Monitored Blood Glucose (SMBG) Profiles
Change from baseline in mean daily blood glucose values were measured using self-monitored blood glucose (SMBG) data collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 2:00 am. The daily mean was calculated as the average of the 8 blood glucose values collected on a particular day. Least Squares (LS) means of change from baseline of the mean of the 8 time points (Daily Mean) were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.
Time frame: 2 separate days in the week preceding the Baseline, Week 4, Week 8, and Week 16 visits.
Change From Baseline in Beta (β)-Cell Function and Insulin Sensitivity as Estimated by the Updated Homeostasis Model Assessment Method (HOMA2)
Homeostasis Model Assessment tool (HOMA2) of β-cell function is a technique for estimating beta-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) using basal serum glucose, and c-peptide concentrations. A fasting blood glucose, c-peptide, and serum insulin level were drawn for purposes of this determination just prior to the mixed meal test.
Time frame: Baseline, 16 weeks
Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%
Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7% or ≤6.5% were analyzed with a logistic regression model with baseline, combination of oral medications, and treatment as factors included in the model.
Time frame: Baseline and 4 and 8 and 16 weeks
Change From Baseline in Body Weight
LS means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.
Time frame: Baseline, 4, 8, and 16 weeks
Change From Baseline in Waist Circumference
Mean change from baseline in waist circumference (a measure of central obesity).
Time frame: Baseline, 16 weeks
Nausea and Dyspepsia Measured by Visual Analog Scale
Participants were asked to score nausea and dyspepsia (abdominal pain and bloating) on a scale of 0 (none) to 100 after the largest meal of the day.
Time frame: One week before and one week after each of the Baseline and Week 4 and Week 8 and Week 16 visits
Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Scores
Gastroparesis Cardinal Symptom Index (GCSI) is a participant-completed questionnaire designed to assess the severity of symptoms consistent with delayed gastric emptying (nausea/vomiting, abdominal bloating, and stomach fullness) at each study visit. GCSI scores ranged from 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, to 5=very severe.
Time frame: Baseline and 4 and 8 and 16 weeks
Number of Participants With a Hypoglycemic Event
A documented hypoglycemic episode is defined as an event which is associated with a measured blood glucose of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \[mmol/L\]), even if it was not associated with symptoms, signs, or treatment. A severe hypoglycemic episode is defined as an event with a measured blood glucose of \<50mg/dL. Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 4, 8, and 16 weeks
Rate of Hypoglycemia Per 30 Days
Hypoglycemic episodes are defined as an event which is associated with reported signs and/or symptoms of hypoglycemia (for example, sweating, shakiness, tachycardia, etc.) or a documented blood glucose (BG) concentration of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \[mmol/L\]), even if it was not associated with symptoms, signs, or treatment. The rate is the average number of days out of 30 that a participant reported hypoglycemia. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 16 weeks
Change From Baseline in Lipids
Lipids include total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides.
Time frame: Baseline, 16 weeks
Participants Perception of Medication Effectiveness Using the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire
The Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire consisted of: 2 items in which respondents were asked about their satisfaction with their diabetes medication over the past week using a 6-point scale ranging from 1 "completely dissatisfied" to 6 "completely satisfied"; 10 items in which respondents were asked about the effectiveness of their diabetes medications in the past week using a 4-point scale ranging from 1 "all of the time" to 4 "none of the time"; and 15 items asking respondents to indicate the frequency of physical side effects in the past week using a 4-point scale ranging from 1 "all of the time" to 4 "none of the time." These items were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. The percentage of participants that rated their general health as good or better are summarized.
Time frame: Baseline and 4 and 8 and 16 weeks
Validation of the Psychometric Properties of the Perceptions About Medications - Diabetes, Short Version (PAM-D-S) Questionnaire
This purpose of this outcome measure was to validate the PAM-D-S questionnaire for future use. Please refer to Outcome Measure #14 for a description of the PAM-D-S questionnaire and results collected. A preliminary analysis indicated modifications to the questionnaire were required and further study is necessary to complete the validation. Therefore, the PAM-D-S questionnaire was not validated as a part of Study H9X-MC-GBCJ.
Time frame: Baseline and 4 and 8 and 16 weeks
Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC)
The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve \[AUC\] at steady state from time zero to 168 hours after study drug administration).
Time frame: Time zero to 168 hours after study drug administration at 4, 8, and 16 weeks
| Milestone | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Started | 65 | 65 | 66 | 66 |
| Received at least one dose of study drug | 65 | 65 | 66 | 66 |
| Completed | 56 | 58 | 58 | 60 |
| Not completed | 9 | 7 | 8 | 6 |
| Withdrew: Adverse event | 4 | 4 | 3 | 1 |
| Withdrew: Entry criteria not met | 1 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 2 | 3 |
Once weekly injections of LY2189265 (titrated and non-titrated doses) compared to placebo on blood glucose were evaluated. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline glycosylated hemoglobin (HbA1c).
| percentage of glycosylated hemoglobin | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) in Overweight and Obese Participants With Type 2 Diabetes Mellitus | -1.52 ± 0.12 | -1.29 ± 0.12 | -1.28 ± 0.12 | -0.27 ± 0.12 |
Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means of change were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.
| millimoles per liter (mmol/L) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Fasting Blood Glucose | -2.64 ± 0.33 | -2.04 ± 0.34 | -2.09 ± 0.34 | -0.49 ± 0.32 |
Glucose excursion in response to a standardized solid mixed meal test was evaluated at baseline (randomization) and at Week 16, or at early termination. Each of the 2 standardized meal tests required participants to fast starting at 2200 hours the night prior to the test. A standardized breakfast meal was provided to the participant (approximately 550 kilocalorie \[Kcal\], 103 grams \[g\] carbohydrates, 22 g protein, and 8.5 g fat) and was to be consumed within 15 minutes. Serial venous blood samples were taken at the start of the meal (fasting \[0\]) and 30, 60, 90, 120, and 180 minutes after the start of the meal. Least Squares (LS) means of change in mean glucose area under the curve excursion following a test meal were calculated adjusting for treatment, combination of oral medications, and baseline.
| millimoles per liter (mmol/L)*minute | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Baseline (n=63, n=62, n=66, n=63) | 11.03 ± 5.02 | 11.12 ± 4.77 | 10.32 ± 4.93 | 10.76 ± 4.37 |
| Week 16 (n=52, n=56, n=54, n=59) | 8.16 ± 4.58 | 9.92 ± 5.32 | 8.85 ± 4.94 | 10.94 ± 4.79 |
Change from baseline in mean daily blood glucose values were measured using self-monitored blood glucose (SMBG) data collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 2:00 am. The daily mean was calculated as the average of the 8 blood glucose values collected on a particular day. Least Squares (LS) means of change from baseline of the mean of the 8 time points (Daily Mean) were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.
| milligrams per deciliter (mg/dL) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Week 4 (n=34, n=38, n=35, n=41) | -31.19 ± 5.85 | -35.94 ± 5.30 | -31.66 ± 5.36 | -8.10 ± 5.06 |
| Week 8 (n=34, n=41, n=38, n=41) | -43.00 ± 5.88 | -40.68 ± 5.43 | -36.02 ± 5.35 | -14.58 ± 5.38 |
| Week 16 (n=41, n=50, n=46, n=49) | -37.49 ± 5.89 | -41.79 ± 5.25 | -32.52 ± 5.40 | -8.67 ± 5.30 |
Homeostasis Model Assessment tool (HOMA2) of β-cell function is a technique for estimating beta-cell function (HOMA2-%B) and insulin sensitivity (HOMA2-%S) using basal serum glucose, and c-peptide concentrations. A fasting blood glucose, c-peptide, and serum insulin level were drawn for purposes of this determination just prior to the mixed meal test.
| percentage of HOMA2 | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| HOMA2-%B | 45.61 ± 55.20 | 44.26 ± 93.89 | 39.20 ± 45.56 | 1.04 ± 41.12 |
| HOMA2-%S | 3.58 ± 18.51 | -1.65 ± 17.19 | 0.46 ± 13.78 | 2.46 ± 12.23 |
Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7% or ≤6.5% were analyzed with a logistic regression model with baseline, combination of oral medications, and treatment as factors included in the model.
| percentage of participants | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| HbA1c levels <7.0%, Baseline | 3.1 | 4.6 | 1.5 | 4.5 |
| HbA1c levels ≤6.5%, Baseline | 0.0 | 1.5 | 0.0 | 0.0 |
| HbA1c levels <7.0%, Week 4 | 15.4 | 30.8 | 22.7 | 7.6 |
| HbA1c levels ≤6.5%, Week 4 | 4.6 | 7.7 | 3.0 | 1.5 |
| HbA1c levels <7%, Week 8 | 41.5 | 47.7 | 47.0 | 15.2 |
| HbA1c levels ≤6.5%, Week 8 | 20.0 | 26.2 | 18.2 | 1.5 |
| HbA1c levels <7%, Week 16 | 53.8 | 50.8 | 56.1 | 15.2 |
| HbA1c levels ≤6.5%, Week 16 | 32.3 | 32.3 | 33.3 | 4.5 |
LS means of change from baseline were calculated using analysis of covariance (ANCOVA) adjusting for treatment, combination of oral medications, and baseline.
| kilograms (kg) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| 4 weeks (n=63, n=63, n=65, n=65) | -1.28 ± 0.23 | -1.08 ± 0.23 | -0.50 ± 0.22 | -0.06 ± 0.22 |
| 8 weeks (n=61, n=60, n=63, n=64) | -2.12 ± 0.31 | -1.67 ± 0.32 | -1.39 ± 0.31 | -0.12 ± 0.31 |
| 16 weeks (n=63, n=63, n=65, n=65) | -2.51 ± 0.38 | -1.40 ± 0.38 | -1.58 ± 0.37 | -0.07 ± 0.38 |
Mean change from baseline in waist circumference (a measure of central obesity).
| centimeters (cm) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Waist Circumference | -1.92 ± 4.24 | -1.51 ± 4.56 | -1.33 ± 4.21 | 0.20 ± 3.40 |
Participants were asked to score nausea and dyspepsia (abdominal pain and bloating) on a scale of 0 (none) to 100 after the largest meal of the day.
| units on a scale | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Nausea, Week before Baseline (n=52, 57, 61, 57) | 4.81 ± 10.50 | 3.56 ± 6.46 | 3.70 ± 5.76 | 3.35 ± 5.83 |
| Nausea, Week after Baseline (n=42, 46, 50, 50) | 5.07 ± 8.58 | 3.85 ± 6.46 | 3.86 ± 5.96 | 2.25 ± 4.82 |
| Ab pain, Week before Baseline (n=52, 57, 61, 57) | 5.66 ± 11.37 | 3.55 ± 9.14 | 4.04 ± 7.15 | 3.63 ± 6.58 |
| Ab pain, Week after Baseline (n=42, 46, 50, 50) | 5.82 ± 9.41 | 4.89 ± 13.35 | 4.51 ± 8.60 | 2.86 ± 7.27 |
| Bloating, Week before Baseline (n=52, 57, 61, 57) | 11.49 ± 16.80 | 8.11 ± 18.04 | 10.21 ± 15.32 | 9.30 ± 18.65 |
| Bloating, Week after Baseline (n=42, 46, 50, 50) | 8.95 ± 12.90 | 10.10 ± 16.64 | 9.17 ± 15.61 | 8.42 ± 20.05 |
| Nausea, Week before Week 4 (n=42, 55, 52, 59) | 6.74 ± 10.89 | 6.88 ± 11.47 | 7.97 ± 15.33 | 4.10 ± 7.32 |
| Nausea, Week after Week 4 (n=49, 58, 59, 54) | 18.13 ± 24.52 | 12.28 ± 19.46 | 7.91 ± 12.39 | 4.10 ± 7.57 |
| Ab pain, Week before Week 4 (n=42, 55, 52, 59) | 6.28 ± 9.53 | 7.74 ± 13.89 | 6.38 ± 11.13 | 4.45 ± 9.19 |
| Ab pain, Week after Week 4 (n=49, 58, 59, 54) | 12.47 ± 20.44 | 9.31 ± 15.77 | 4.94 ± 8.89 | 4.59 ± 7.88 |
| Bloating, Week before Week 4 (n=42, 55, 52, 59) | 13.56 ± 19.51 | 12.00 ± 19.17 | 9.95 ± 13.27 | 7.96 ± 15.77 |
| Bloating, Week after Week 4 (n=49, 58, 59, 54) | 19.90 ± 25.61 | 13.40 ± 21.15 | 10.23 ± 13.88 | 8.40 ± 14.96 |
| Nausea, Week before Week 8 (n=50, 51, 55, 58) | 10.90 ± 20.26 | 5.45 ± 10.63 | 7.39 ± 13.53 | 6.11 ± 12.59 |
| Nausea, Week after Week 8 (n=50, 54, 54, 55) | 8.58 ± 12.88 | 5.57 ± 11.50 | 8.69 ± 13.41 | 5.30 ± 11.52 |
| Ab pain, Week before Week 8 (n=50, 51, 55, 58) | 10.76 ± 19.06 | 5.76 ± 12.47 | 5.12 ± 9.01 | 6.65 ± 13.15 |
| Ab pain, Week after Week 8 (n=50, 54, 54, 55) | 7.97 ± 14.72 | 6.87 ± 14.56 | 6.26 ± 11.93 | 6.38 ± 12.74 |
| Bloating, Week before Week 8 (n=50, 51, 55, 58) | 17.65 ± 26.41 | 10.93 ± 17.92 | 11.58 ± 20.13 | 10.12 ± 19.20 |
| Bloating, Week after Week 8 (n=50, 54, 54, 55) | 13.30 ± 18.66 | 11.18 ± 19.56 | 14.50 ± 20.95 | 10.34 ± 17.17 |
| Nausea, Week before Week 16 (n=45, 49, 52, 54) | 9.68 ± 17.79 | 3.31 ± 5.53 | 6.36 ± 10.82 | 5.88 ± 14.41 |
| Nausea, Week after Week 16 (n=45, 48, 49, 53) | 11.09 ± 17.62 | 5.73 ± 10.80 | 7.77 ± 12.25 | 3.40 ± 6.40 |
| Ab pain, Week before Week 16 (n=45, 49, 52, 54) | 6.46 ± 9.48 | 5.68 ± 11.09 | 6.26 ± 12.89 | 6.17 ± 14.24 |
| Ab pain, Week after Week 16 (n=45, 48, 49, 53) | 7.56 ± 14.28 | 5.99 ± 11.53 | 6.44 ± 12.58 | 5.19 ± 11.72 |
| Bloating, Week before Week 16 (n=45, 49, 52, 54) | 12.57 ± 18.93 | 9.06 ± 16.78 | 12.26 ± 20.06 | 9.30 ± 18.60 |
| Bloating, Week after Week 16 (n=45, 48, 49, 53) | 14.06 ± 20.46 | 11.11 ± 19.62 | 14.04 ± 22.26 | 8.84 ± 17.44 |
Gastroparesis Cardinal Symptom Index (GCSI) is a participant-completed questionnaire designed to assess the severity of symptoms consistent with delayed gastric emptying (nausea/vomiting, abdominal bloating, and stomach fullness) at each study visit. GCSI scores ranged from 0=none, 1=very mild, 2=mild, 3=moderate, 4=severe, to 5=very severe.
| units on a scale | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Stomach fullness, Week 4 (n=62, n=60, n=65, n=65) | 0.55 ± 1.51 | 0.57 ± 1.35 | 0.62 ± 1.26 | 0.35 ± 1.39 |
| Stomach fullness, Week 8 (n=59, n=60, n=59, n=63) | 0.46 ± 1.65 | 0.30 ± 1.33 | 0.71 ± 1.54 | 0.25 ± 1.39 |
| Stomach fullness, Week 16 (n=63, n=62, n=65, n=65) | 0.21 ± 1.58 | 0.27 ± 1.28 | 0.51 ± 1.34 | 0.15 ± 1.34 |
| Bloating, Week 4 (n=62, n=60, n=65, n=65) | 0.35 ± 0.10 | 0.28 ± 0.93 | 0.19 ± 0.91 | 0.28 ± 0.84 |
| Bloating, Week 8 (n=59, n=60, n=60, n=63) | 0.41 ± 1.34 | 0.13 ± 1.02 | 0.14 ± 1.32 | 0.18 ± 0.92 |
| Bloating, Week 16 (n=63, n=62, n=65, n=65) | 0.02 ± 1.04 | 0.11 ± 0.94 | 0.32 ± 1.32 | 0.28 ± 0.86 |
| Nausea/Vomiting, Week 4 (n=62, n=60, n=64, n=65) | 0.25 ± 0.71 | 0.19 ± 0.71 | 0.22 ± 0.52 | 0.03 ± 0.40 |
| Nausea/Vomiting, Week 8 (n=59, n=60, n=60, n=63) | 0.46 ± 0.97 | 0.04 ± 0.64 | 0.28 ± 0.62 | 0.02 ± 0.39 |
| Nausea/Vomiting, Week 16 (n=63, n=62, n=65, n=65) | 0.20 ± 0.64 | -0.01 ± 0.59 | 0.27 ± 0.48 | -0.01 ± 0.36 |
A documented hypoglycemic episode is defined as an event which is associated with a measured blood glucose of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \[mmol/L\]), even if it was not associated with symptoms, signs, or treatment. A severe hypoglycemic episode is defined as an event with a measured blood glucose of \<50mg/dL. Participant reports of hypoglycemic events were collected at the beginning of each visit starting at Baseline. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Documented Hypoglycemic Event, Week 4 | 17 | 17 | 17 | 9 |
| Documented Hypoglycemic Event, Week 8 | 11 | 13 | 15 | 10 |
| Documented Hypoglycemic Event, Week 16 | 6 | 10 | 7 | 8 |
| Severe Hypoglycemic Event, Week 4 | 0 | 0 | 0 | 0 |
| Severe Hypoglycemic Event, Week 8 | 0 | 0 | 0 | 0 |
| Severe Hypoglycemic Event, Week 16 | 0 | 0 | 0 | 0 |
Hypoglycemic episodes are defined as an event which is associated with reported signs and/or symptoms of hypoglycemia (for example, sweating, shakiness, tachycardia, etc.) or a documented blood glucose (BG) concentration of ≤70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \[mmol/L\]), even if it was not associated with symptoms, signs, or treatment. The rate is the average number of days out of 30 that a participant reported hypoglycemia. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per 30 days | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Rate of Hypoglycemia Per 30 Days | 0.69 ± 1.29 | 0.80 ± 1.60 | 0.70 ± 1.18 | 0.24 ± 0.54 |
Lipids include total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides.
| millimoles per liter (mmol/L) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Cholesterol (n=61, n=60, n=60, n=62) | -0.34 (-3.44 to 2.28) | -0.05 (-1.37 to 2.69) | -0.09 (-2.18 to 4.77) | 0.18 (-1.91 to 2.56) |
| LDL-Cholesterol (n=61, n=60, n=60, n=61) | -0.26 (-2.80 to 2.23) | -0.09 (-1.22 to 1.58) | -0.07 (-1.39 to 4.27) | 0.10 (-0.83 to 2.12) |
| HDL-Cholesterol (n=61, n=60, n=60, n=61) | -0.02 (-0.33 to 0.41) | -0.02 (-0.37 to 0.54) | 0.00 (-0.26 to 0.23) | 0.00 (-0.24 to 0.26) |
| Triglycerides (n=61, n=60, n=60, n=61) | -0.16 (-7.63 to 2.22) | -0.02 (-4.84 to 2.96) | -0.16 (-4.25 to 2.96) | 0.00 (-7.39 to 5.69) |
The Perceptions about Medications - Diabetes, Short Version (PAM-D-S) questionnaire consisted of: 2 items in which respondents were asked about their satisfaction with their diabetes medication over the past week using a 6-point scale ranging from 1 "completely dissatisfied" to 6 "completely satisfied"; 10 items in which respondents were asked about the effectiveness of their diabetes medications in the past week using a 4-point scale ranging from 1 "all of the time" to 4 "none of the time"; and 15 items asking respondents to indicate the frequency of physical side effects in the past week using a 4-point scale ranging from 1 "all of the time" to 4 "none of the time." These items were exploratory items taken from a Diabetes Medicines Survey and had not been validated as a scale. The percentage of participants that rated their general health as good or better are summarized.
| percentage of participants | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| Baseline | 72.7 | 87.0 | 87.5 | 89.1 |
| Week 4 | 83.3 | 90.2 | 87.5 | 87.0 |
| Week 8 | 82.9 | 90.5 | 90.9 | 88.6 |
| Week 16 | 92.1 | 90.2 | 86.0 | 93.0 |
This purpose of this outcome measure was to validate the PAM-D-S questionnaire for future use. Please refer to Outcome Measure #14 for a description of the PAM-D-S questionnaire and results collected. A preliminary analysis indicated modifications to the questionnaire were required and further study is necessary to complete the validation. Therefore, the PAM-D-S questionnaire was not validated as a part of Study H9X-MC-GBCJ.
No measurements were reported for this outcome.
The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve \[AUC\] at steady state from time zero to 168 hours after study drug administration).
| nanograms*hour/milliliter (ng*h/mL) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 |
|---|---|---|---|
| Pharmacokinetics (PK) of LY2189265 - Area Under the Concentration Time Curve (AUC) | 14587 ± 5674 | 7876 ± 3064 | 4488 ± 1746 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.0/2.0 Milligram (mg) LY2189265 | — | 1/65 (1.5%) | 41/65 (63.1%) |
| 1.0/1.0 Milligram (mg) LY2189265 | — | 2/65 (3.1%) | 35/65 (53.8%) |
| 0.5/1.0 Milligram (mg) LY2189265 | — | 3/66 (4.5%) | 40/66 (60.6%) |
| Placebo | — | 1/66 (1.5%) | 36/66 (54.5%) |
| Event | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/65 | 0/65 | 0/66 | 1/66 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/65 | 1/65 | 0/66 | 0/66 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/65 | 1/65 | 0/66 | 0/66 |
| PancreatitisGastrointestinal disorders | 0/65 | 0/65 | 1/66 | 0/66 |
| Septic shockInfections and infestations | 0/65 | 0/65 | 0/66 | 1/66 |
| HallucinationPsychiatric disorders | 0/65 | 0/65 | 1/66 | 0/66 |
| Cryptogenic organising pneumoniaRespiratory, thoracic and mediastinal disorders | 0/65 | 0/65 | 1/66 | 0/66 |
| Event | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 9/65 | 11/65 | 9/66 | 5/66 |
| Abdominal distensionGastrointestinal disorders | 9/65 | 5/65 | 3/66 | 4/66 |
| DiarrhoeaGastrointestinal disorders | 9/65 | 4/65 | 5/66 | 5/66 |
| VomitingGastrointestinal disorders | 7/65 | 1/65 | 3/66 | 2/66 |
| ConstipationGastrointestinal disorders | 6/65 | 3/65 | 6/66 | 0/66 |
| NasopharyngitisInfections and infestations | 5/65 | 4/65 | 2/66 | 3/66 |
| Abdominal painGastrointestinal disorders | 4/65 | 2/65 | 5/66 | 3/66 |
| Abdominal pain upperGastrointestinal disorders | 4/65 | 3/65 | 2/66 | 2/66 |
| Upper respiratory tract infectionInfections and infestations | 0/65 | 0/65 | 1/66 | 4/66 |
| Early satietyGeneral disorders | 0/65 | 3/65 | 1/66 | 0/66 |
Participants who received at least one dose of LY2189265 or Placebo.
| Age, Continuous(years) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 54.49 ± 11.28 | 57.46 ± 11.72 | 58.65 ± 11.69 | 55.96 ± 12.49 | 56.65 ± 11.84 |
| Sex: Female, Male(Participants) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 31 | 30 | 31 | 37 | 129 |
| Male | 34 | 35 | 35 | 29 | 133 |
| Race/Ethnicity, Customized(participants) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| African | 4 | 6 | 5 | 4 | 19 |
| Caucasian | 36 | 39 | 40 | 36 | 151 |
| East Asian | 1 | 0 | 0 | 0 | 1 |
| Hispanic | 23 | 20 | 19 | 26 | 88 |
| Native American | 1 | 0 | 2 | 0 | 3 |
| Region of Enrollment(participants) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| United States | 56 | 56 | 57 | 58 | 227 |
| Puerto Rico | 9 | 9 | 9 | 8 | 35 |
| Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 8.43 ± 0.99 | 8.25 ± 0.99 | 8.25 ± 0.89 | 8.05 ± 0.82 | 8.24 ± 0.93 |
| Body Mass Index (BMI)(kilograms per square meters (kg/m^2)) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 34.24 ± 4.11 | 33.85 ± 3.95 | 33.70 ± 4.11 | 33.89 ± 4.31 | 33.92 ± 4.10 |
| Body Weight(kilograms (kg)) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 98.60 ± 18.41 | 96.68 ± 16.51 | 94.76 ± 16.53 | 94.74 ± 15.21 | 96.18 ± 16.68 |
| Duration of Diabetes(years) | 1.0/2.0 Milligram (mg) LY2189265 | 1.0/1.0 Milligram (mg) LY2189265 | 0.5/1.0 Milligram (mg) LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 8.63 ± 6.92 | 8.13 ± 5.43 | 8.97 ± 7.62 | 7.48 ± 5.41 | 8.30 ± 6.41 |
The record gives a start of Apr 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 5 years 11 months after primary completion. A results delay was requested in Dec 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide